• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
    • News & Updates
  • Donate
Home / Arthritis News / High Disease Activity During Pregnancy Associated with Lower Birth Weight

High Disease Activity During Pregnancy Associated with Lower Birth Weight

December 15, 2009 By Arthritis Center

Rheumatoid Vasculitis

Rheumatoid arthritis disease activity tends to improve during pregnancy, even when disease modifying agents are stopped.  However, a minority of women with rheumatoid arthritis will continue to have active disease during pregnancy, and may require additional immunosuppression.  Prior studies have yielded conflicting reports on the influence of active disease during pregnancy.  Here, de Man et al (Arthritis Rheum 2009; 60(11): 3196) explore pregnancy outcomes in women with rheumatoid arthritis.

Methods

Outcomes of first, singleton pregnancies of Caucasian mothers enrolled in the Dutch Pregnancy-Induced Amelioration of Rheumatoid Arthritis (PARA) study were tracked between 2002 – 2007.  The birth weight standard deviation score (SDS) was calculated according to the newborns gender, gestational age, and birth weight.  The associations of disease activity and clinical characteristics with pregnancy outcomes were explored.  Reference groups included the Netherlands Perinatal Registry (PRN) and the Generation R Study.

Results

A total of 152 women met inclusion criteria for the study.  The average age of participants was 32 years.  At delivery, the median RA disease duration was 70 months, with a wide range of variability (8 – 356 months).  Compared to reference populations, RA participants were slightly older on average for their first delivery, less likely to smoke during pregnancy, and more likely to use artificial reproduction techniques.  Medications used during pregnancy included prednisone (n=50; mean dose ~ 8 mg/day), sulfasalazine (n=40), and hydroxychloroquine (n=2).  Generally, medication use was stable over the course of the entire pregnancy within individual women.  During pregnancy, RA disease activity tended to decrease, from a mean DAS28 of 3.8 units during the first trimester to 3.3 units in the third.

On average, mean birth weight and gestational age at delivery for the RA group were normal and comparable to non-RA obstetrical comparison cohorts.   Elective caesarian and instrumental vaginal deliveries were more frequent in the RA group compared to comparison cohorts.  Caesarian delivery was more frequent in women with moderate to high RA disease activity during the third trimester compared to women with low disease activity (22% vs. 10%; p=0.04).  In contrast, the rate of instrumental vaginal delivery did not differ by third trimester disease activity.  The incidence rates for prematurity (8.6%), small for gestational age (3.3%), hypertensive disorders of pregnancy (6.6%) and preeclampsia (0.7%) were low and comparable to reference obstetrical cohorts, overall.

Disease activity during the third trimester was inversely associated with both the actual birth weight and birth weight SDS, even after adjusting for pertinent sociodemographic and lifestyle characteristics.  Prednisone use was associated with higher actual birth weights, but was not significantly associated with the birth weight SDS.  In addition, women taking prednisone during pregnancy delivered an average of one week earlier than women who did not take prednisone (39.9 vs. 38.8 weeks, respectively).  Sulfasalazine use during pregnancy did was not associated with any adverse outcomes.

Conclusions

While pregnancy outcomes were generally similar for women with RA compared to the general obstetrical population, high disease activity during pregnancy and prednisone use may affect birth weight and gestation.

Editorial Comment

This is one of the largest studies prospectively exploring pregnancy outcomes in RA.  In general, the study confirms that RA disease activity tends to improve during pregnancy and that, in general, pregnancy outcomes are favorable for most women.  For women with high disease activity during pregnancy, the question of whether to use prednisone is an important one, since one may be trading one adverse effect for another.  From the results of this study, the preferred strategy may be to treat high disease activity during pregnancy with sulfasalazine rather than prednisone.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Recent News

Exercise Tips for Arthritis Patients

How Does Exercise Affect my Joints? How Frequently Should I Be Exercising? Should I Lose Weight for Exercise to be

Risks and Benefits of Biologic Medications

Victoria Ruffing, RN, BC, Director of Patient Education at the Johns Hopkins Arthritis Center, shares the risks and benefits of biologic for

How to Manage Rheumatoid Arthritis Flares

Through research, doctors have a clearer understanding of how flares can impact a patient on a personal and emotional level. Dr. Uzma Haque

Complementary & Alternative Medicines for Psoriatic Arthritis

There are many complementary & alternative medicines and practices that have been found to be beneficial in curbing arthritis pain,

I can’t be a runner because I have Rheumatoid Arthritis (RA), right?

Dr. Manno discusses running and Rheumatoid Arthritis. Is it an option for the RA patient?

News Categories

  • Ankylosing Spondylitis News
  • Fibromyalgia News
  • Gout News
  • Lupus News
  • Osteoarthritis News
  • Osteoporosis News
  • Psoriatic Arthritis News
  • Rheumatoid Arthritis News
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2025 Johns Hopkins Arthritis Center
Patient Privacy